Keyphrases
Clinical Trials
100%
H3 K27-altered
87%
Diffuse Midline Glioma
87%
ONC201
87%
Paxalisib
87%
Consensus Framework
87%
Older Adults
87%
Conductive Phase
87%
Pediatric Low-grade Glioma
87%
Preadolescent children
87%
Phase III Clinical Trial
87%
Diffuse Intrinsic Pontine Glioma
37%
Clinical Efficacy
29%
ClpP
25%
Tumor
17%
Functional Endpoints
17%
Interpretable Results
17%
Targeted Combination
17%
Clinical Trial Design
17%
Targeted Inhibitors
17%
Clinical Implementation
17%
Clinical Trial Phase II
17%
Clinical Trial Phases
17%
Novel Therapies
17%
Clinical Endpoints
17%
Therapy Development
17%
Targeted Therapeutics
17%
Treatment Duration
17%
Early Phase Clinical Trials
17%
Optimal Dosing Strategy
17%
Quality of Life
17%
Global Approach
17%
Predictive Biomarker
17%
Mitochondrial Proteases
12%
AKT1
12%
Metabolic Adaptation
12%
PI3K Signaling
12%
Pharmacokinetic Properties
12%
Patient Survival
12%
Biological Approach
12%
Response Mechanism
12%
Redox
12%
Tricarboxylic Acid Cycle (TCA cycle)
12%
Recurring
12%
Pharmacodynamic Properties
12%
PIK3CA mutation
12%
Feature Influence
12%
Brain Penetrant
12%
Proteolysis
12%
Genomic Features
12%
Medicine and Dentistry
Ganglioglioma
87%
Clinical Trial
87%
Pediatrics
87%
Biological Marker
17%
Treatment Duration
17%
Clinical Trial Design
17%
Targeted Therapeutic Agent
17%
Therapy Development
17%
Quality of Life
17%
Tumor
17%
Diseases
17%
Established Treatment
17%
Pharmacology, Toxicology and Pharmaceutical Science
Pontine Glioma
87%
Pharmacokinetics
29%
Tricarboxylic Acid
29%
Clinical Trial
29%
Protein Kinase B Inhibitor
29%
Endopeptidase Clp
29%
Childhood Cancer
29%
Pharmacodynamics
29%